Global Alzheimer Disease Genetic Testing Market Growth (Status and Outlook) 2023-2029
The global Alzheimer Disease Genetic Testing market size is projected to grow from US$ 109.6 million in 2022 to US$ 372.2 million in 2029; it is expected to grow at a CAGR of 19.1% from 2023 to 2029.
United States market for Alzheimer Disease Genetic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Alzheimer Disease Genetic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Alzheimer Disease Genetic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Alzheimer Disease Genetic Testing players cover Mega Genomics, Blueprint Genetics, Generi-Biotech, RxHomeTest, Kashi Labs, 23andMe, LabCorp, Empower DX and SolGent, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Alzheimer's disease is a neurodegenerative disorder that affects memory, cognitive functions, and behavior. While there is no cure for Alzheimer's disease, early detection and treatment can help slow the progression of the disease. Genetic testing can be a useful tool in identifying individuals who may be at higher risk of developing Alzheimer's disease.
LPI (LP Information)' newest research report, the “Alzheimer Disease Genetic Testing Industry Forecast” looks at past sales and reviews total world Alzheimer Disease Genetic Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Alzheimer Disease Genetic Testing sales for 2023 through 2029. With Alzheimer Disease Genetic Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alzheimer Disease Genetic Testing industry.
This Insight Report provides a comprehensive analysis of the global Alzheimer Disease Genetic Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Alzheimer Disease Genetic Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Alzheimer Disease Genetic Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alzheimer Disease Genetic Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alzheimer Disease Genetic Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Alzheimer Disease Genetic Testing market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Early-Onset Alzheimer Disease
Late-Onset Alzheimer Disease
Segmentation by application
Online
Offline
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mega Genomics
Blueprint Genetics
Generi-Biotech
RxHomeTest
Kashi Labs
23andMe
LabCorp
Empower DX
SolGent
CapitalBio
Genex Diagnostics
Sansure
Please note: The report will take approximately 2 business days to prepare and deliver.